Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.64 |
| ▸ | HTR2C | P28335 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | GRB2 | P62993 | 1/20 | 0.59 |
| ▸ | SLC7A5 | Q01650 | 7/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | XIAP | P98170 | 1/20 | 0.59 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.56 |
| ▸ | NOS3 | P29474 | 2/20 | 0.55 |
| ▸ | NOS1 | P29475 | 2/20 | 0.55 |
| ▸ | NOS2 | P35228 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.53 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29557134 | 1.00 | HTR2A (0.64) | HTR2AHTR2CHTR2BGRB2SLC7A5 | |
| SCHEMBL44156 | 1.00 | HTR2A (0.64) | HTR2AHTR2CHTR2BGRB2SLC7A5 | |
| SCHEMBL44155 | 1.00 | HTR2A (0.64) | HTR2AHTR2CHTR2BGRB2SLC7A5 | |
| SCHEMBL29478401 | 1.00 | HTR2A (0.64) | HTR2AHTR2CHTR2BGRB2SLC7A5 | |
| Hydrochloric Acid SCHEMBL10584250 | 0.98 | HTR2A (0.62) | HTR2AHTR2CHTR2BGRB2SLC7A5 | |
| Hydrochloric Acid SCHEMBL6775624 | 0.98 | HTR2A (0.62) | HTR2AHTR2CHTR2BGRB2SLC7A5 | |
| Hydrochloric Acid SCHEMBL6775619 | 0.98 | HTR2A (0.62) | HTR2AHTR2CHTR2BGRB2SLC7A5 | |
| SCHEMBL6831079 | 0.88 | PPARG (0.60) | HTR2AHTR2CHTR2BGRB2SLC7A5 | |
| SCHEMBL16131653 | 0.88 | HTR2A (0.69) | HTR2AHTR2CHTR2BEPHX1DPP4 | |
| SCHEMBL19943590 | 0.88 | HTR2A (0.69) | HTR2AHTR2CHTR2BEPHX1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083834-A1 | CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | TRANSFERT PLUS LP (CA) | 2026-03-26 | — | — | US | disclosed |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | NEW YORK UNIVERSITY (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2025245483-A1 | METHODS AND COMPOSITIONS | FLAGSHIP PIONEERING INNOVATIONS VII, LLC (US) | 2025-11-27 | — | — | WO | disclosed |
| US-20250361273-A1 | METHODS AND COMPOSITIONS | FLAGSHIP PIONEERING INNOVATIONS VII, LLC | 2025-11-27 | — | — | US | disclosed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-12371461-B2 | Nemo coiled coil mimics and methods of using same | NEW YORK UNIVERSITY (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250229081-A1 | NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2025-07-17 | — | — | US | disclosed |
| US-20050124548-A1 | Peptide antiangiogenic drugs | HENKIN JACK (US) | 2005-06-09 | — | — | US | disclosed |
| US-6774211-B1 | Peptide antiangiogenic drugs | ABBOTT LABORATORIES | 2004-08-10 | — | — | US | disclosed |
| US-6716963-B1 | OLIGOPEPTIDES | ABBOTT LABORATORIES | 2004-04-06 | — | — | US | disclosed |
| US-20030148936-A1 | Bioactive peptides | ALPHARMA AS. | 2003-08-07 | — | — | US | disclosed |
| EP-1263471-A2 | ANTIMICROBIAL COMPOUNDS AND FORMULATIONS | ALPHARMA AS (NO) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001066147-A2 | ANTIMICROBIAL COMPOUNDS AND FORMULATIONS | ALPHARMA AS (NO) | 2001-09-13 | — | — | WO | disclosed |
| EP-1109831-A2 | CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | disclosed |
| EP-1109827-A2 | BIOACTIVE PEPTIDES | ALPHARMA AS (NO) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000012542-A2 | CYTOTOXIC LACTOFERRIN DERIVATIVES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
| WO-2000012541-A2 | CYTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES | ALPHARMA AS (NO) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | HTR2A 4346/4885HTR2C 4711/4885HTR2B 4355/4885 |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | HTR2A 4741/4885HTR2C 4698/4885HTR2B 4285/4885 |
| US-12371461-B2 | Nemo coiled coil mimics and methods of using same | COIL, CALCOCO2, NCAPH | HTR2A 2891/4885HTR2C 2681/4885HTR2B 3072/4885 |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | JAK2, JAK1, CHMP4B | HTR2A 4511/4885HTR2C 4432/4885HTR2B 4360/4885 |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | HTR2A 3518/4885HTR2C 3285/4885HTR2B 3413/4885 |
| US-20050124548-A1 | Peptide antiangiogenic drugs | VEGFA, NPPA, FLT1 | HTR2A 1318/4885HTR2C 4190/4885HTR2B 1289/4885 |
| US-20030148936-A1 | Bioactive peptides | VIP, NGLY1, HM13 | HTR2A 4824/4885HTR2C 4873/4885HTR2B 4421/4885 |
| US-20260083834-A1 | CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | VSIG8, MICA, CD74 | HTR2A 4794/4885HTR2C 4856/4885HTR2B 4849/4885 |
| US-20250361273-A1 | METHODS AND COMPOSITIONS | MC4R, GPR119, MC2R | HTR2A 219/4885HTR2C 265/4885HTR2B 373/4885 |
| US-20260001924-A1 | NEMO COILED COIL MIMICS AND METHODS OF USING SAME | DDX21, PHAX, RBX1 | HTR2A 2915/4885HTR2C 3112/4885HTR2B 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.